Company Overview - Teladoc Health, Inc. (NYSE:TDOC) is recognized as a leading healthcare AI stock, providing virtual healthcare services across various domains including general medical, chronic condition management, mental health, and specialty care [4] Recent Developments - On December 16, Teladoc announced that board director J. Eric Evans will retire in 2026 and will not stand for reelection at the 2026 Annual Meeting of Stockholders [1] - Barclays initiated coverage on Teladoc with an Equal Weight rating and a price target of $8.50, reflecting a neutral stance on the US healthcare technology and distribution industry [2] - Bank of America Securities analyst Allen Lutz reiterated a Hold rating on Teladoc and lowered the price target to $8, citing mixed results in user growth metrics, with BetterHelp showing a year-over-year decline in monthly active users (MAUs) despite some sequential improvement [3] Performance Metrics - BetterHelp's MAUs experienced a year-over-year decline, while Livongo's MAUs reached their highest levels since early 2024, although these figures remain below the peaks seen in 2022, indicating insufficient growth to drive significant revenue gains in the near term [3]